Download PDF
Previous article
Go back to website
Next article
If you have problems to see the content please click here
Other users also viewed these articles
Metronomic oral vinorelbine in a real-world population of advanced non-small cell lung cancer patients
Fernanda Estevinho; Rita Gomes; Direndra Hasmucrai; Fernando Barata;
Pulmonol. 2022;28:368-75
Unresectable stage III non-small cell lung cancer: Insights from a Portuguese expert panel
A. Araújo; A. Barroso; B. Parente; C. Travancinha; E. Teixeira; F. Martelo; G. Fernandes; G. Paupério; H. Queiroga; I. Duarte; J.D. da Costa; M. Soares; P. Borralho; P. Costa; P. Chinita; T. Almodôvar; F. Barata;
Pulmonol. 2024;30:159-69
Results from phase II, open-label study of anti-tumoral activity of first-line erlotinib in advanced/metastatic NSCLC patients with EGFR activating mutations, in Portugal: The MuTAR study
F. Barata; H. Queiroga; E. Teixeira; T. Almodovar; M. Soares; B. Parente; J.C. Mellidez; P. Alves; A. Antunes;
Pulmonol. 2021;27:175-7